Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Poliovirus receptor (PVR), also known as CD155, is a type I transmembrane glycoprotein belonging to the immunoglobulin superfamily and the nectin-like protein family (UniProt P15151). Originally identified as the primary entry receptor for poliovirus on host mucosal epithelial cells, it is now recognized as a pivotal immune checkpoint ligand in oncology. In healthy physiological states, CD155 is expressed at low levels and facilitates cell-cell adhesion at adherens junctions and mediates cell migration. In the context of cancer, CD155 is frequently overexpressed on tumor cells and antigen-presenting cells, where it interacts with the inhibitory receptors TIGIT and CD96 on T cells and natural killer (NK) cells to promote immune evasion (NIH). Conversely, it can bind the activating receptor DNAM-1 (CD226) to stimulate anti-tumor immunity, but this balance is often disrupted in the tumor microenvironment. Therapeutic development focuses on monoclonal antibodies like NTX-1088 and TGI-5 that directly target CD155, as well as engineered oncolytic polioviruses like lerapolturev that exploit CD155 for tumor-selective entry and lysis ( NCT05378425). Additionally, the CD155-TIGIT axis is a major target for a broad class of anti-TIGIT antibodies currently in clinical trials for various solid tumors.
Directly blocking CD155 to prevent its interaction with inhibitory receptors TIGIT and CD96, thereby restoring T-cell and NK-cell mediated anti-tumor activity; utilizing CD155 as a portal for oncolytic viral entry and subsequent tumor cell lysis; and indirectly modulating the CD155 axis via TIGIT blockade to favor activating signals through DNAM-1.
8 more in the full profile.
Source types: Peer-reviewed publication · Trial registry. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Poliovirus receptor (PVR) (PVR).